Oral allopurinol to prevent hyperamylasemia and acute pancreatitis after endoscopic retrograde cholangiopancreatography

Table 1 Demographics and ERCP data

	Allopurinol n = 85	Placebo n = 85	P
Age	53.5 ± 18.9	52.8 ± 19.8	0.82
Gender M/F	36/49	34/51	0.86
Diagnosis
Benign
Choledocholitiasis	35	35	0.51
Iatrogenic injury of the biliary tract	11	14	0.48
Chronic pancreatitis	3	1	0.31
Chronic hepatopathy	2	2	0.60
Sphincter of oddi dysfunction	2	2	0.60
Mirizzi’s syndrome	1	0	0.50
Malignant
Pancreatic adenocarcinoma	11	12	0.82
Cholangiocarcinoma	4	5	0.50
Periampullary carcinoma	2	2	0.60
Gallbladder cancer	0	1	0.50
Normal cholangiography	8	5	0.48
Failed procedure	6	6	0.61
Total	85	85